Developing SHP2-based combination therapy for KRAS-amplified cancer

Developing SHP2-based combination therapy for KRAS-amplified cancer

Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated that SHP2 phosphatase, which acts to promote KRAS and downstream MAPK pathway activation, is a target in these tumors when combined with MEK...

Full description

Bibliographic Details
Main Authors: Tianxia Li, Osamu Kikuchi, Jin Zhou, Yichen Wang, Babita Pokharel, Klavdija Bastl, Prafulla Gokhale, Aine Knott, Yanxi Zhang, John G. Doench, Zandra V. Ho, Daniel V.T. Catenacci, Adam J. Bass
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-02-01
Series:JCI Insight
Subjects:
Oncology
Online Access:https://doi.org/10.1172/jci.insight.152714

Internet

https://doi.org/10.1172/jci.insight.152714

Similar Items